Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial

Jarushka Naidoo, Johan Vansteenkiste, Corinne Faivre‐Finn, Mustafa Özgüroğlu, Shuji Murakami, Rina Hui, Xavier Quantin, Helen Broadhurst, Michael Newton, Piruntha Thiyagarajah, Scott Antonia